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ABSTRACT 
In this paper we study the effectiveness of three well known polymers: inulin, 
Soluplus and PVP in stabilizing amorphous form of nimesulide (NMS) drug. The re-
crystallization tendency of pure drug as well as measured drug-polymer systems were 
examined at isothermal conditions by using broadband dielectric spectroscopy (BDS), and at 
non-isothermal conditions by differential scanning calorimetry (DSC). Our investigation has 
shown that the crystallization half-life time of pure NMS at 328 K is equal to 33 minutes. We 
found that this time can be prolonged to 40 years after adding to NMS 20% of PVP polymer. 
This polymer proved to be the best NMS’s stabilizer, while the worst stabilization effect was 
found after adding the inulin to NMS. Additionally, our DSC, BDS and FTIR studies indicate 
that for suppression of NMS’s re-crystallization in NMS-PVP system, the two mechanisms 
are responsible: the polymeric steric hindrances as well as the antiplastization effect excerted 
by the excipient. 
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INTRODUCTION 
Nimesulid (NMS) is a non-steroidal anti-inflamatory drug (NSAIDs) which shows 
high anti-inflammatory, antipyretic, and analgesic activities in addition to low toxicity, and a 
high therapeutic index
1
. Like many non-steroidal anti-inflammatory drugs, NMS is 
characterized by low aqueous solubility (≈ 0.01 mg/mL), and poor dissolution rate2. The 
commonly employed strategies to increase solubility and dissolution rate of poorly soluble 
drugs are based on using an cyclodextrin, macronization, and convertion the Active 
Pharmaceutical Ingredients (APIs) to their salt forms
3
. Another, an alternative way is 
preparing the amorphous form of those compounds. Recently, it has been often reported that 
pharmaceuticals prepared in the amorphous form are significantly more soluble, have higher 
dissolution rate, and have greater bioavailability than their crystalline counterparts
4,5,6
. 
Unfortunately, it should be highlighted that, amorphous APIs are in general physically 
unstable and, consequently, during storage or manufacturing they may revert to the crystalline 
form and, consequently, lose their superior properties.
7,8,9,10
 
It is believed that the main factor affecting physical stability of disordered APIs is 
molecular mobility
11,12
. It has been demonstrated many times that the most efficient 
experimental tool to investigate molecular dynamics of glass-forming systems is broadband 
dielectric spectroscopy (BDS)
13,14
. This technique enables the determination of the 
characteristic time of  molecular reorientation over a broad range of frequencies (over 12 
decades) and temperatures. Such a wide f and T range allows the detection of various 
relaxation processes. In the supercooled liquid, the structural (α) relaxation, which originates 
from cooperative movements of many molecules, is usually the most prominent relaxation 
process observed in the dielectric spectra. In the glassy state it is possible to observe faster 
local motions, which have an inter- or intramolecular origin. Additionally, using dielectric 
spectroscopy, the kinetics of crystallization at isothermal conditions can be monitored. Such 
studies are extremely valuable, especially for physical stability tests. 
The objective of the current work was to convert nimesulid drug to its amorphous 
form and examine by means of BDS its physical stability. Since, our measurements indicate 
that amorphous NMS is extremely physically unstable system, a lot of attention has been paid 
to find an efficient method of stabilization this material. A promising strategy for inhibiting 
devitrification of amorphous drugs is to disperse them into a polymeric matrix.
15,16,17
 
Therefore we decided to check how three well known and commonly used in pharmaceutical 
industry polymers: inulin (INL), Soluplus (SOP) and poly(vinylpyrrolidone) (PVP) stabilize 
nimesulid drug. It is worth noting that each of these additives belong to different groups of 
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polymers. SOP represents a very complex copolymeric system,whereas both INL and PVP 
have strictly one polymerizable unit. In contrast to inulin, which has a stiff molecular chain, 
poly(vinylpyrrolidone) belongs to a group of polymers with highly flexible structures. 
In order to achieve our aim and answer the question of which polymer can better suppress 
NMS’s crystallization, we investigated the molecular dynamics and kinetics of crystallization 
of pure NMS and the following binary mixtures: NMS+PVP, NMS+SOP and NMS+INL. The 
crystallization process in nimesulide has been examined at both isothermal and non-
isothermal conditions. The latter was measured by using differential scanning calorimetry 
(DSC). Finally, we also tried to establish which stabilization mechanism is involved in case of 
the investigated binary mixtures. 
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EXPERIMENTAL METHODS 
Materials 
Nimesulide (NMS) (Kemprotec Limited, UK), inulin DP-23 (INL) (Frutafix TEX, Sensus, 
Netherlands), polyvinyl pyrrolidone 10 kDa (PVP) (Sigma Aldrich, Ireland) and SoluplusTM 
(SOP) (BASF, Germany). 
 
Preparation of physical mixtures  
Physical mixtures of NMS and polymers, respectively; INL, PVP or SOP were prepared by 
milling at room temperature using mixer mill MM 200 (Retsch, Germany) for 15 min at 
mixing frequency of 25 1/s. 
 
Differential Scanning Calorimetry (DSC) 
Thermodynamic properties of NMS, NMS + 5% wt. INL, NMS + 5% wt. SOP, NMS 
+ 5% wt. PVP, NMS + 20% wt. SOP and NMS + 20% wt. PVP were examined using a 
Mettler–Toledo DSC 1 STARe System. The measuring device was equipped with HSS8 
ceramic sensor having 120 thermocouples and liquid nitrogen cooling station. The instrument 
was calibrated for temperature and enthalpy using zinc and indium standards. Crystallization 
and melting points were determined as the onset of the peak, whereas the glass transition 
temperature as the midpoint of the heat capacity increment. The samples were measured in an 
aluminum crucible (40 μL). All measurements were carried out in range from 270 K to 
430/435 K with a variety – 5 K/min, 10 K/min, 20 K/min and 30 K/min – of heating rates. 
 
Broadband Dielectric Spectroscopy (BDS) 
Dielectric measurements of NMS, NMS + 5% wt. INL, NMS + 5% wt. SOP, NMS + 
5% wt. PVP, NMS + 20% wt. SOP and NMS + 20% wt. PVP were carried out using a Novo-
Control GMBH Alpha dielectric spectrometer, in the frequency range from 10
-1
 Hz to 10
6
 Hz, 
at temperatures from 193 K to 328 K with steps of 2.5 K. The temperature was controlled by a 
Quattro temperature controller with temperature stability better than 0.1 K. Dielectric studies 
of all samples were performed immediately after fast cooling of the melt in a parallel-plate 
cell made of stainless steel (diameter 15 mm and a 0.1 mm gap with Teflon spacers). 
Crystallization kinetics for all samples were carried out at four different temperatures, as 
follows: pure NMS at 318 K, 323 K, 328 K and 330.5 K; NMS + 5% INL at 318 K, 323 
K, 328 K and 333 K; NMS + 5% SOP at 328 K, 330.5 K, 333 K and 338 K; NMS + 5% PVP 
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at 328 K, 330.5 K, 333 K and 338 K; NMS + 20% SOP at 343 K, 353 K, 358 K and 363 K; 
NMS + 20% PVP at 360.5 K, 363 K, 365.5 K and 368 K. 
 
Fourier Transform Infrared Spectroscopy (FTIR) 
FTIR was performed using a Spectrum One FT-IR Spectrometer (Perkin Elmer, Connecticut, 
USA) equipped with Spectrum Software version 6.1. A spectral range of 450-4000 cm
-1
, 
resolution of 4 cm
-1
, scan number of 10 and scan speed of 0.2 cm/s were used. KBr disks were 
produced by direct compression, using a pressure of approximately 10 bar for 1 minute. A 
sample loading of 1% was used. The spectra were normalized and background corrected. 
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MOLECULAR DYNAMICS OF PURE NIMESULIDE ABOVE AND BELOW THE GLASS TRANSITION 
Dielectric loss spectra of amorphous nimesulide were measured in both the 
supercooled liquid and glassy state by using BDS technique. In this experiment, the 
temperature was increased from 193 K to 328 K in steps of 2.5 K. Representative spectra are 
shown in Figure 1. For better visualization of obtained dielectric results, the data have been 
divided into two panels (a and b). Panel a of Figure 1 presents spectra collected above the 
glass transition temperature. Herein, we can see one well-resolved loss peak connected to the 
α-relaxation process. This relaxation mode moves toward higher frequencies with increasing 
temperature and at T > 323 K its intensity begins to rapidly decrease. Such a drop in the 
intensity of α-relaxation is caused by cold crystallization of the sample and it reflects the 
degree of reduction in amorphous fraction.
18
 In order to determine the value of βKWW for 
NMS, and to check whether temperature aﬀ ects the shape of the structural relaxation process, 
we constructed so-called masterplot (see inset Figure 1a) by horizontal shifting of spectra 
(taken at deferent temperatures from 300.65 to 323.15 K) to superimpose on the reference 
spectrum at 303.15 K. As can be seen in presented masterplot, the shape of the structural 
relaxation in NMS is not changing with temperature, and the parameter βKWW is the same for 
all spectra and equal to 0.72. According to the Shamblin observations, narrower α-relaxation 
peaks correspond to higher physical stability of amorphous APIs.
19
 However, as our studies 
show, the amorphous NMS reveals quite a strong tendency to recrystallize, despite of fact that 
the α-relaxation peak is quite narrow. Similar behavior was previously observed in the case of 
ezetimibe, celecoxib and sildenafil.
20,21,22,23 
 
  
Figure 1. Dielectric loss spectra of NMS obtained on heating. The panel (a) presents spectra collected above the glass 
transition temperature, whereas panel (b) shows spectra below the Tg. In the inset of panel (a) we present the 
masterplot that was constructed by superimposed dielectric spectra at nine different temperatures above Tg. The 
dashed black line represents the KWW fit with the βKWW = 0.72. 
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Panel b of Figure 1 presents dielectric spectra collected at temperatures below Tg. In this 
temperature region the structural relaxation becomes too slow to be observed and only 
secondary relaxation processes may be visible. As can be easily seen in Figure 1b, NMS has 
only one secondary (β) process, which, just like the α-mode, moves toward higher frequencies 
with increasing temperature. However, this process is less sensitive to temperature changes 
when compared to the behavior of the α-relaxation. 
From analysis of dielectric loss spectra collected above and below Tg, we determined 
the temperature dependence of α- and β-relaxation times (see Figure 2). Firstly, to obtain the 
values of τα and τβ at various temperatures, the asymmetric α-peak and  symmetric β-process 
have been fitted using the Havrilak–Negami (HN) and the Cole–Cole (CC) function, 
respectively.
24
 The empirical HN approach is given by the formula: 
  baHN
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where ε’ and ε” are real and imaginary parts of complex dielectric permittivity, ε∞ is high 
frequency limit permittivity, Δε is dielectric strength, τHN is the HN relaxation time, and a and 
b represent symmetric and asymmetric broadening of the relaxation peak. This function is 
equivalent to the CC function when the parameter b is equal to 1.In this special case Eq. (1) 
fits NMS’s β-relaxation.25 Next, the fitting parameters were used to calculate the τα and τβ by 
means of the equation: 
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Figure 2. The relaxation map of NMS drug. Temperature dependence of τα in the supercooled liquid has been 
described by the VFT equation. The α-relaxation times in the glassy state were found by horizontal shift of the 
structural relaxation peak from the region above the glass transition to the region below Tg. The temperature 
dependence of τβ was fitted using the Arrhenius equation. 
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In order to parameterize the τα(T) dependence we employed the Vogel–Fulcher–
Tammann (VFT) equation: 







 
0
exp)(
TT
B
T   (3) 
where τ∞, T0, and B are fitting parameters.
26,27.28
 Their values for NMS are equal to: log10(τ∞/s) 
= -19.4 ± 0.7, T0 = 216 ± 4, and B = 3711 ± 310. Based on the VFT parameters we estimated 
Tg (defined as τα = 100 s) of NMS as 291 K. The glass transition temperature determined by 
this method is in  good agreement with the Tg obtained from calorimetric studies (TgDSC 10K/min 
= 294 K – see Figure 5) as well as with the literature data.29 From VFT fits we also calculated 
the value of the fragility parameter for NMS as mp = 82. This parameter, also called steepness 
index, is a measure of deviation from Arrhenius behavior of the τα(T) dependence and is 
defined as follows:
30
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Typical values of steepness index are between 16 and 200. The higher the value of mp, the 
more fragile (less strong) liquids are. The fragility is frequently considered as a key parameter 
for researchers dealing with physical stability of amorphous drugs because it has been implied 
that strong materials are more stable than fragile ones.
31
 However, very recently a few 
exceptions tothis correlation were found. In the case of NMS we found that its low physical 
stability correlates to a high value of fragility. Thus NMS satisfies the above mentioned 
correlation. 
 
ISOTHERMAL AND NON-ISOTHERMAL CRYSTALLIZATION KINETICS STUDIES OF PURE NMS 
ABOVE THE GLASS TRANSITION TEMPERATURE 
In this section we shall concentrate on the crystallization kinetics of NMS drug. To 
fully characterize the tendency of amorphous NMS to devitrify, both the isothermal and non-
isothermal kinetics of crystallization have been investigated.  
The isothermal cold crystallization kinetics of NMS were studied by using BDS 
technique. In this experiment, we performed time-depending dielectric measurements at four 
different temperatures (318 K, 323 K, 328 K and 330.5 K). For each measurement a new 
sample was prepared by employing the vitrification method. Using dielectric spectroscopy the 
crystallization process can be followed by measuring both the real (ε’) and imaginary (ε”) 
parts of the complex dielectric permittivity. In the ε’, devitrification is reflected by a decrease 
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in the static permittivity (Figure 3a), whereas in the ε” by a decrease in the intensity of the α-
loss peak (Figure 3b). 
 
Figure 3. Dielectric spectra of the real (a) and imaginary (b) parts of the complex dielectric permittivity during an 
isothermal cold crystallization of NMS at fixed temperature equal to 238 K. 
Usually, the progress of cold crystallization is analyzed by normalized dielectric constant 
(ε’N), defined as follows: 
)(')0('
)(')0('
)('






t
tN  (5) 
where ε’(0) is the dielectric constant at the beginning of the crystallization process, ε’(t) is the 
value of dielectric constant at time t, and ε’(∞) is the long-time limiting value. The normalized 
kinetics curves of NMS are presented together in Figure 4. 
  
Figure 4. Normalized dielectric constant ε’N as a function of time from crystallization processes occurring at: 318.15, 
323.15, 328.15 and 330.65 K. The lower inset presents the Avrami plots in terms of eq. 6 for each crystallization 
temperature in the time ranges where the dependences are linear. The upper inset shows the temperature dependence 
of logk – here, the solid line denotes the linear fit of eq. 7. 
11 
 
To analyze the time dependence of ε’N we used the Avrami model.
32
It should be mentioned 
that this model is the most commonly applied method of analyzing the crystallization process 
at a fixed temperature, and is described by the following formula: 
))(exp(1)(' nN tKt   (6) 
where K=k
n
 is the rate constant, and n is the Avrami parameter that is directly related to the 
nucleation dimensionality. Usually parameter n falls in the range of 2-3.
33
 To determine 
values of both K and n parameters we prepared a so-called Avrami plot (see lower inset of 
Figure 4), which is based on the equation:
34
 
tntKtN log)(log)))('1ln(log(     (7) 
As can be clearly seen, if the ))'1ln(log( N  vs. tlog  is linear, the n and logK can be 
determined as the slope and the intercept of this dependence, respectively. Avrami parameters 
obtained in this way are shown in Table 1. The value of Avrami exponent n changes in the 
standard way, i.e. decreases with temperature (from 2.9 to 1.8), indicating that the 
crystallization process of NMS at isothermal conditions is three-and two-dimensional at high 
and low temperatures, respectively. Additionally, since the parameter K increases with 
increasing crystallization temperature, we can conclude that the dominant mechanism of 
isothermal devitrification in the case of NMS is the diffusion of molecules.
35
 
T [K] n logK 
318.15 2.86 ± 0.01 - 11.33 ± 0.04 
323.15 2.30 ± 0.02 - 8.49 ± 0.07 
328.15 2.18 ± 0.03 - 7.36 ± 0.10 
330.65 1.89 ± 0.01 - 5.98 ± 0.03 
Table 1. Isothermal cold crystallization kinetics parameters of NMS obtained from the Avrami model according to eq. 
7. 
 In order to estimate the activation energy of isothermal cold crystallization (EaI) for 
NMS we plotted the logarithm of k (k=K
1/n
) versus reciprocal temperature (see upper inset of 
Figure 4). Since the logk vs. 1000/T dependence, in measured temperature range, is linear, the 
value of EaI may be found by fitting Arrhenius law to the experimental points: 
e
RT
E
kk aI logloglog 0   (8) 
where k0 and EaI are fitting parameters, and R is the universal gas constant. It should be 
pointed out the temperature dependence of crystallization might not be linear if the measured 
temperature range would be wider. Crystallization activation energy of pure NMS obtained in 
this way is equal to 126 ± 8 kJ/mol. 
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The cold crystallization kinetics of NMS was also studied at non-isothermal 
conditions. For these measurements the DSC technique was employed. During the experiment 
the sample was heated from 270 K to 430 K at different heating rates ϕ = 5, 10, 20 and 30 
K/min. As can be seen in Figure 5 and Table 2, with increasing heating rate the values of Tg, To 
(temperature of crystallization onset) and Tp (temperature of crystallization peak) shift toward 
higher temperatures. 
Heating Rate [K/min] To [K] Tp [K] Tg [K] 
5 342 348 293 
10 348 354 294 
20 352 360 296 
30 359 365 298 
Table 2. Temperatures of crystallization onsets, peaks and glass transitions determined from DSC thermograms 
measured at different heating rates. 
  
Figure 5. DSC thermograms of NMS measured at different heating rates (5 K/min, 10 K/min, 20 K/min, 30 K/min). 
The upper inset shows an enlarged temperature region of the glass transitions. The lower inset presents an Augiss and 
Bennett plot for the crystallization peak of NMS. The orange line indicates the linear fit to eq. 9. 
Based on the parameters collected in Table 2, we determined the activation energy of non-
isothermal cold crystallization (EaNI) of NMS by using the Augiss and Bennett approach (see 
lower inset of Figure 5):
36
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where CAB and EaNI are fitting parameters and R is the universal gas constant. The activation 
energy obtained using this method is significantly greater (over 35%) than the crystallization 
activation energy of NMS at isotheral conditions, and is equal to 210 ± 14 kJ/mol. 
Further analysis of non-isothermal cold crystallization kinetics of NMS was carried 
out based on the temperature dependence of relative degree of crystallinity X.
37
 The X(T) 
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dependence, for each heating rate, is presented in Figure 6a, and was obtained by using the 
following equation: 
 
 



T
T
c
T
T
c
dTdTdH
dTdTdH
TX
0
0)(  (10) 
where T0 and T∞ represent the temperatures at which the crystallization process begins and 
ends, respectively, while dHc denotes the enthalpy of crystallization that is released during an 
infinitesimal temperature range dT.  
 
Figure 6. (a) The temperature dependence of crystallization degree determined from eq. 10 at different heating rates. 
(b) The time dependence of crystallization degree obtained by transforming the temperature scale into the time scale 
using eq. 11. The inset presents the Avrami plots, which have been constructed from the non-isothermal 
crystallization data for NMS.  
After determination of the X(T) dependence it was possible to transform the temperature scale 
into the time scale and consequently obtain X(t) function. For this transformation the equation 
listed below has been used: 

0TTt

  (11) 
where t denotes the time of crystallization and ϕ is the heating rate. The plots of the relative 
degree of crystallinity as a function of time at different heating rates are shown in Figure 6b. 
X(t) dependence was next analyzed by the Avrami model – inset of Figure 6b. Obtained values 
of n’ and logK’ are shown in Table 3.   
ϕ [K/min] n’ logK’ 
5  5.86 ± 0.05 -13.20 ± 0.11 
10 6.78 ± 0.05 -14.07 ± 0.11 
20 6.52 ± 0.08 -11.89 ± 0.14 
30 5.57 ± 0.07 -9.04 ± 0.11 
Table 3. Non-isothermal cold crystallization kinetics parameters of NMS obtained from the Ozawa model according 
to eq. 11. 
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As can be seen, the n’ parameter changes from 5.6-6.8, indicating that the non-isothermal cold 
crystallization of NMS is much more complicated than crystallization at fixed temperature, 
where parameter n oscillated around 2.5. This is probably due to the formation of more than 
one crystallographic structure at non-isothermal conditions. The formation of various 
polymorphs also might explain higher Ea of crystallization at non-isothermal conditions than 
at fixed temperature. 
 
THE EFFECTS OF POLYMERIC ADDITIVES ON PHYSICAL STABILITY OF AMORPHOUS NMS 
In this part of the paper we shall investigate how three polymers that are frequently 
used in the pharmaceutical industry, Soluplus (SOP), inulin (INL) and poly(vinylpyrrolidone) 
(PVP), affect the physical stability of the amorphous form of NMS. Since one of the main 
factors affecting the re-crystallization of disordered pharmaceuticals is molecular mobility, 
the NMS + polymer systems have been investigated by means of BDS technique. The 
dielectric loss spectra of systems containing NMS drug and the polymeric additive were 
measured at the temperature range from 173.15 K to 338.15 K with step of 2.5 K. The 
representative spectra of the binary amorphous mixtures with 5% of the polymers are 
presented in Figure 7. As can be seen, all three mixtures exhibit one well resolved secondary 
relaxation process below the glass transition temperature (lower panels of Figure 7 a, b and c). 
All these processes are similar to that found in pure NMS, and therefore it is concluded that 
they originate from dipole reorientation of the drug’s molecules. Above the Tg a well 
pronounced relaxation peak, corresponding to the structural α-relaxation process, is observed 
in the dielectric spectra (see upper panels of Figure 7 a, b and c). It moves toward higher 
frequencies with increasing temperature, and its intensity begins to rapidly decrease at T = 
326 K for NMS + 5% INL, and T = 343 K – for NMS + 5% SOP and NMS + 5% PVP. This 
drop in intensity of the α-peak is due to the crystallization onset.  
15 
 
 
Figure 7. Dielectric loss spectra of binary amorphous mixtures of NMS drug and 5% weight of INL (black panels), 
SOP (cyan panels) and PVP (pink panels) obtained on heating. The upper panels present spectra collected above the 
glass transition temperature, whereas lower panels show spectra below the Tg. 
As can be seen, the devitrification of the mixture containing 5% of INL begins at 
lower temperature than for the other mixtures. Therefore we can conclude that INL stabilizes 
NMS the least. Similar result has been obtained by using DSC experiment (see Figure 8). The 
heating rate applied in these DSC experiments is equal to 10 K/min. 
 
Figure 8. The DSC thermograms of pure NMS, NMS + 5% of INL, NMS + 5% of SOP, and 5% of PVP measured at 
heating rates equal to 10 K/min. 
In order to check how higher concentration of PVP and SOP will affect on NMS’s 
physical stability, we additionally prepared for further studies the mixtures of NMS + SOP 
and, NMS + PVP with a higher (20% weight) concentration of the polymers. From the 
analysis of dielectric loss spectra collected both above and below the Tg of all examined 
systems (i.e. NMS + 5% INL, NMS + 5% SOP, NMS + 5% PVP, NMS + 20% SOP and NMS 
+ 20% PVP), the temperature dependences of α- and β- relaxation times for all of these 
mixtures (see Figure 9) were obtained. To determine the τα and τβ we employed the same 
method used previously for pure NMS. 
16 
 
 
Figure 9. Relaxation maps of NMS and mixtures containing NMS and 5% or 20% polymer (INL,SOP or PVP). 
Temperature dependence of τα in the supercooled liquid has been described by VFT equation. The temperature 
dependence of τβ was fitted by using the Arrhenius equation. 
The Vogel-Fulcher-Tamman equation was used to describe the τα(T) dependences, 
while the τβ(T) dependences were fitted to the Arrhenious law. The fitting parameters for the 
VFT and the Arrhenius equations are collected in Table 4. As can be seen in Figure 9 the 
greatest changes in the temperature dependence of structural relaxation times can be observed 
in the case of the mixtures containing PVP, suggesting that this polymer may be the most 
successful at stabilizing the amorphous form of NMS drug. 
Sample 
α-process β-process 
T0 [K] log τ∞-α B log τ∞-β Eβ [kJ/mol] 
Pure NMS 216.1 ± 3.8 -19.4 ± 0.7 3711 ± 310 -14.2 ± 0.2 41.9 ± 0.9 
NMS + 5% INL 182.4 ±5.4 -24.8 ± 1.0 6609 ± 568 -14.4 ± 0.1 42.4 ± 0.5 
NMS + 5% SOP 210.9 ± 3.9 -19.2 ± 0.6 3881 ± 299 -11.8 ± 0.2 30.4 ± 0.7 
NMS + 5% PVP 213.0 ± 2.2 -19.1 ± 0.4 3841 ± 171 -12.1 ± 0.1 31.5 ± 0.5 
NMS + 20% SOP 198.1 ± 6.6 -19.3 ± 0.8 4499 ± 485 -13.4 ± 0.1 33.9 ± 0.4 
NMS + 20% PVP 237.9 ± 4.8 -15.7 ± 0.6 2588 ± 259 -12.6 ± 0.1 30.8 ± 0.3 
Table 4. The fitting parameters from the VFT and Arrhenius equations. 
In order to check how effectively the stability of disordered NMS was improved by 
using the examined polymers, the isothermal kinetics of crystallization, at four various 
temperatures for NMS’s mixtures containing 5% INL, 5% SOP, 5% PVP, 20% SOP and 20% 
PVP, have been measured. Since the tested mixtures exhibit different tendencies to crystallize, 
it was not always possible to measure them at the same temperatures. The crystallization 
kinetics studies were carried out at 318 K, 323 K, 328 K and 333 K for NMS + 5% INL; at 
328 K, 330.5 K, 333 K and 338 K for NMS + 5% SOP; at 328 K, 330.5 K, 333 K and 338 K 
for NMS + 5% PVP, at 343 K, 353 K, 358 K and 363 K for NMS + 20% SOP; and at 360.5 
K, 363 K, 365.5 K and 368 K for NMS + 20% PVP. For each measurement a new sample was 
prepared by the vitrification method.  
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The method used to analyze the crystallization kinetics of all samples was analogous 
to that used for pure NMS, i.e. using the Avrami model. The temperature dependences of the 
logarithm of the crystallization rate k are presented in Figure 10. This plot has the 
fundamental purpose of answering the following two questions: i) how do the polymeric 
additives change the crystallization activation energy?; and ii) what is the difference in the 
logk values of pure NMS and various binary amorphous mixtures at fixed temperature? 
   
Figure 10. The temperature dependence of log(k) of pure NMS and binary amorphous mixtures containing the drug 
and 5% or 20% polymer (INL, SOP or PVP). Solid lines in this figure denote the linear fit to the Arrhenius equation. 
The inset a presents the crystallization half-life time of NMS and all prepared mixtures checked at a temperature of 
328 K. The inset b present the log10k as a function of log10τα. 
The crystallization activation energy of the mixture containing 5% INL is comparable 
to the value of 126 kJ/mol estimated for the pure NMS. In contrast, both 5% additive of SOP 
and 5% additive of PVP result in an increase in this value. The Ea of NMS + 5% SOP and 
NMS + 5% PVP are equal to 146 ± 6 kJ/mol and 205 ± 16 kJ/mol, respectively. A greater 
amount of SOP polymer (20%) brings about an increase in the activation energy of 
crystallization to 156 ± 4 kJ/mol. However, the most significant effect has been observed after 
adding 20% PVP to NMS. In this case, the activation energy reached the highest value of 324 
± 28 kJ/mol. 
A useful measure of the capability of polymers to stabilize the NMS drug is the 
crystallization half-life time (t1/2).
38
 It defines the time required to reach half of the final 
crystallinity and it has been calculated for each measured sample at T = 328 K by using the 
following relation: 
n
K
t
/1
2/1
2ln






  (12) 
The values of t1/2 are plotted versus concentration of polymers in the inset of Figure 10. As can 
be seen, the half-life time at T = 328 K for pure NMS is equal to 33 min, while for samples 
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containing 5% INL, SOP and PVP t1/2 = 1.8 h, t1/2 = 6.7 h and t1/2 = 8.8 h, respectively. If the 
concentration of SOP and PVP is raised to 20% the values of t1/2 are equal to 7.3 days for SOP 
and 40 years for PVP.  
The results presented above indicate that INL has indeed the least stabilizing effect on 
the examined drug from all tested polymers, while the highest inhibition of crystallization was 
observed with mixtures containing PVP – the polymer which has the greatest impact on 
NMS’s molecular mobility. 
In order to find out if the suppression of the drug’s re-crystallization in NMS-PVP 
mixtures is caused only by the antiplastization effect, we examined how the glass transition 
temperatures of NMS-PVP mixtures change with the polymer concentration. It has been 
demonstrated many times that if additional interactions between the drug and polymer exist, 
the experimentally determined Tg values for different concentrations of the additive should 
deviate from the theoretical dependence that was proposed by Gordon and Taylor:
39,40
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where w1 and w2 are the weight fractions of each component, and Tg1 and Tg2 correspond to 
the glass transition temperature of each component. Tg is the glass transition temperature of 
the mixture, while K is a measure of the interaction between the components, and can be 
defined as follows:
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where ΔCp denotes the change in heat capacity at Tg.  
It can be clearly seen in Figure 11 that the Tg values of the NMS-PVP mixture grow 
continuously with increasing polymer content. A noticeable discrepancy between the 
predicted values of glass transition temperature and the experimentally determined data was 
observed. Therefore one can expect that, apart  from  an antiplasticizing effect also the 
specific interactions between the drug and excipient, and/or polymeric steric hindrances, may 
also play an important role in improving NMS’s physical stability in binary amorphous NMS-
PVP systems. 
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Figure 11. Glass transition temperatures of the NMS−PVP mixtures. The pink circles correspond to the 
experimentally determined Tg values, whereas the dashed line represents the prediction of the 
Gordon−Taylor/Kelley−Bueche equation, calculated from the Tg values of the pure NMS and pure PVP K15. In the 
inset the chemical structures of both compounds are presented. 
To check if specific chemical interactions indeed exist in NMS-PVP mixtures, we 
performed a series of FTIR experiments. Table 5 presents the position of the main absorption 
peaks (band assignment was carried out based on work of Galico et al.
42
 and Tajber et al.
43
) 
and Figure 11 shows selected FTIR spectra of the amorphous samples. It can be seen that, 
with exception of the CO stretching vibration of PVP, the bands remained practically at the 
same position, regardless of the sample composition. The υCO band showed, however, a blue 
shift as the NMS content in the sample increased, which indicates that this chemical group 
becomes less H-bonded in the presence of the drug, most likely due to the more hydrophobic 
environment limiting the moisture content. Overall, FTIR analysis indicates that NMS and 
PVP did not interact in the amorphous phase and the overall net of H-bond interactions 
decreased, consistent with large negative deviations of the Tg values from the prediction, as 
presented in Figure 11. Consequently, the suppression of NMS’s crystallization in NMS-PVP 
mixtures should be caused by two mechanisms: the polymeric steric hindrances as well as the 
antiplastization effect exerted by the additive.  
NMS 
(% w/w) 
NMS PVP 
υNH υCCring υaNO2 
ρrNH+ 
ρrCHring
+ υaSO2 
υCNnitro
+ υsNO2 
υsSO2 υCO υCN 
100 3284 1599,1589 1522 1343 1318 1154 N/A N/A 
95 3284 1599,1589 1522 1343 1318 1155 1678 N/A 
90 3285 1599,1588 1521 1343 1317 1154 1680 N/A 
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80 N/A 1598,1588 1524 1341 N/A 1156 1676 N/A 
60 N/A 1597,1587 1523 1341 N/A 1157 1676 N/A 
40 N/A 1596,1587 1523 1341 N/A 1157 1673 1289 
20 N/A 1597,1587 1523 1340 N/A 1156 1670 1289 
10 N/A N/A 1524 1339 N/A 1157 1665 1290 
0 N/A N/A N/A N/A N/A N/A 1664 1290 
Table 5. Position of principal FTIR bands of amorphous NMS, PVP and NMS-PVP mixtures (N/A – not applicable; υ 
– stretching, υa – asymmetric stretching, υs – symmetric stretching, and ρr – rocking vibration). 
 
Figure 12. FTIR spectra of amorphous NMS-PVP systems 
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CONCLUSIONS 
In this paper we investigated how three well known polymers, inulin, Soluplus and 
PVP, affect the physical stability and molecular mobility of amorphous nimesulide drug. 
Using broadband dielectric spectroscopy the molecular mobility of pure drug and mixtures 
containing 5% or 20% wt. of the polymers has been completely characterized. Besides the α-
relaxation, NMS and binary amorphous mixtures exhibit one secondary mode. Both the BDS 
and DSC studies have shown that pure drug easily re-crystallized. To get a full picture of the 
tendency of amorphous NMS to devitrify, we measured isothermal and non-isothermal 
kinetics of crystallization. Based on the data we calculated the isothermal and non-isothermal 
crystallization activation energies. Their values are equal to 126 ± 8 kJ/mol and 210 ± 14 
kJ/mol, respectively. The significantly greater (over 35%) value of EaNI than EaI can result 
from the formation of polymorphs during NMS’s crystallization. We also found that the 
dominant mechanism of devitrification in the case of NMS drug is the diffusion of molecules.  
In order to experimentally investigate the effectiveness of crystallization inhibition of 
the drug by polymeric additives we measured the isothermal crystallization kinetics of all 
tested substances. Based on these studies we calculated the crystallization activation energies 
as well as the crystallization half-life times at 328 K of all measured substances. The Ea and 
t1/2(at 328 K) of pure NMS, NMS + 5% INL, NMS + 5% SOP, NMS + 5% PVP, NMS + 20% 
SOP, and NMS + 20% PVP are equal to 126 ± 8 kJ/mol and 33 min, 126 ± 14 kJ/mol and 1.8 
h, 146 ± 6 kJ/mol and 6.7 h, 205 ± 16 kJ/mol and 8.8 h, 156 ± 4 kJ/mol and 7.3 days, and 324 
±28 kJ/mol and 40 years, respectively.  
Our studies indicate that INL is the worst stabilizer for NMS, whereas the most 
significant stabilization effect can be achieved by adding the polymer PVP to NMS. Probably, 
the two mechanisms are responsible for suppression of NMS’s re-crystallization in NMS-PVP 
system: the polymeric steric hindrances, and the antiplastization effect exerted by the 
excipient. 
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